Research & Development
New Drug Development
Through continuous research, we are trying to move one step closer to the development of a new global and innovative drug.
You can choose to browse SG Medical
website in English, Update your language?
현재 위치가 대한민국으로 추정됩니다. 언어를 업데이트하시겠습니까?
English
Korean
한국어
Through continuous research, we are trying to move one step closer to the development of a new global and innovative drug.
SG Medical Bispecific Unit (SBU) platform is a next-generation therapeutic bispecific antibody platform capable of simultaneously binding to two antigens. This can be used to develop innovative new drugs that can overcome the limitations of monoclonal antibody therapies.
Based on the complement activation mechanism of the novel asymmetric bispecific antibody platform, the anti-cancer effect can be maximized.
Asymmetric antibody structure, enhance complement-dependent cytotoxicity effect
Synergistic anti-cancer effect through simultaneous control of two antigens
High expression yield, one-step purification process
Introduction of next-generation Fc, improving blood half-life and therpeutic efficacy
Pipeline 1 is a bispecific antibody that simultaneously controls CD20, a blood cancer treatment target, and CD55, a complement control target. This therapeutic can overcome the low response rate and resistance of CD20 targetd therapies, which are unmet medical needs for blood cancer. This pipeline was selected as the R&D pipeline of the Korea Drug Development Fund (HN21C0103) in 2021 based on its strong cytotoxic effect on blood cancer cell lines resistant to the CD20 therapies.
Pipeline 2 is a therapeutic bispecific antibody with a mechanism of inducing cancer cell death and inhibiting metastasis through simultaneous control of EGFR, a solid cancer treatment target, and integrin β1, which is involved in cancer metastasis and drug resistance. It is a new concept bispecific antibody for solid cancer treatment that can maximize anticancer effects by introducing the SBU platform and overcome resistance to EGFR-targeted therapies by combining new targets.
It is a humanized antibody developed with SG Medical's own technology, and has completed domestic and PCT applications based on the strong anti-cancer efficacy of single or combined with chemotherapy in lung cancer animal models.